Aurobindo Pharma’s injectable business unit -- AuroMedics has achieved a topline of $50 million in Q2 FY19, a growth of 8% as compared to corresponding quarter previous year. The company has filed a total of 104 injectables, abbreviated new drug applications (ANDAs), out of which 59 have received final approval and one tentative approval.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
